This is a story looking at a study that found familial hypercholesterolemia was more common than previously thought. This condition is associated with an increased risk of heart disease and heart attacks in adults under 40. As a result, researchers are proposing that more kids get screened, and possibly start treatment earlier, to reduce this risk.
One commentator noted: “We really need to pay attention to this” and “It’s reasonable to screen for something that’s common, dangerous and has a treatment that’s effective and safe.” The corollary to this statement is that there is little direct evidence that treating children with medication to lower cholesterol reduces cardiac deaths, and there are plenty of unknowns, such as the costs of screening and labeling very young kids with a disease that may not cause any problems for a long time. The story should have done more to explore both sides of this issue.
Parents want to do everything they can to make sure their children have a long and healthy life, and so a story about a genetic condition being more common than previously thought is likely to be read widely. Unfortunately, the story’s framing takes the stance that finding the risk factors for this disease very early on in life leads to an overall benefit. But the study provides no evidence of that, and parents need to know this.
This was a strong point for the story, which did provide some information on cost. “The study did not address whether screening is cost-effective. In the U.S., cholesterol tests cost around $80 and usually are covered by health insurance, though much lower prices often are negotiated. The study authors in England estimated that if cholesterol testing costs $7 and gene testing costs $300, it would cost $2,900 for every person identified as having the disorder.” We wish the story would have noted the cost of gene testing in the U.S. but otherwise found this satisfactory.
The story also could have noted that although statin drugs are generic and relatively inexpensive, the long-term costs of treatment from childhood onward are likely to be significant.
The story quantified the findings this way: “For every 1,000 people screened in the study, four children and four parents were identified as being at risk for early heart disease. That’s nearly twice as many as most studies in the past have suggested.” That lets us know how many more people might get identified if screening was widened, but readers should also be informed that it isn’t clear if this ultimately reduces cardiac deaths.
The harms of screening including false positives and negatives, overdiagnosis, overtreatment, inappropriate disease labelling and so on are not mentioned.
The story explains how many babies were tested and how they were tested. But, we didn’t get a sense of how reliable these testing methods are, nor what the study’s limitations were.
Instead, the story implied that the study showed that screening kids will lower their risk, with statements like this: “What if a blood test could reveal that your child is at high risk for early heart disease years in the future, giving you a chance to prevent it now?”
The story included numbers on how prevalent this condition is, and the increased risk of heart disease that it carries, though it would have been stronger if it had given specifics on what the baseline risk is versus the 10-fold increase.
The story included independent sources. Also, the story discloses this: “The study was led by Dr. David Wald at Queen Mary University of London. He and another author founded a company that makes a combination pill to prevent heart disease. The work was funded by the Medical Research Council, the British government’s health research agency.”
The alternative here is no screening in early childhood.
Are these sorts of genetic tests available for parents to buy off the shelf, or ask for a referral from a doctor to get? The story doesn’t clarify.
The story establishes the novelty of the study by explaining that it found that this genetic condition is more common than originally thought.
There are two sources who do not appear to be associated with the study.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like